Nicholas Theodosakis, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Melanosis | 5 | 2024 | 93 | 3.470 |
Why?
|
Hyperpigmentation | 5 | 2024 | 116 | 3.240 |
Why?
|
Acne Vulgaris | 4 | 2024 | 352 | 1.950 |
Why?
|
International Classification of Diseases | 2 | 2022 | 937 | 1.070 |
Why?
|
Melanoma | 11 | 2023 | 5706 | 0.950 |
Why?
|
Tretinoin | 1 | 2024 | 524 | 0.740 |
Why?
|
Proto-Oncogene Proteins B-raf | 4 | 2017 | 2059 | 0.650 |
Why?
|
Prenylation | 1 | 2018 | 37 | 0.630 |
Why?
|
Skin Neoplasms | 9 | 2023 | 5863 | 0.580 |
Why?
|
Tissue Embedding | 1 | 2016 | 43 | 0.540 |
Why?
|
Sepharose | 1 | 2016 | 102 | 0.520 |
Why?
|
MAP Kinase Kinase 1 | 1 | 2017 | 331 | 0.500 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2018 | 5341 | 0.450 |
Why?
|
Insurance Coverage | 2 | 2024 | 1946 | 0.430 |
Why?
|
Cell Size | 1 | 2015 | 626 | 0.420 |
Why?
|
Alcoholism | 1 | 2024 | 1980 | 0.420 |
Why?
|
Tetracycline | 2 | 2023 | 216 | 0.410 |
Why?
|
Minocycline | 2 | 2023 | 170 | 0.390 |
Why?
|
Medicaid | 1 | 2024 | 2840 | 0.360 |
Why?
|
Keratolytic Agents | 1 | 2024 | 34 | 0.230 |
Why?
|
Hair Removal | 1 | 2023 | 41 | 0.220 |
Why?
|
Glucose | 1 | 2015 | 4352 | 0.210 |
Why?
|
Isotretinoin | 1 | 2024 | 134 | 0.210 |
Why?
|
Dermatology | 2 | 2024 | 905 | 0.200 |
Why?
|
Lung Neoplasms | 5 | 2022 | 13586 | 0.200 |
Why?
|
Proteomics | 1 | 2016 | 3912 | 0.200 |
Why?
|
Administration, Topical | 1 | 2024 | 703 | 0.200 |
Why?
|
Melanoma, Experimental | 2 | 2016 | 559 | 0.200 |
Why?
|
Endorphins | 1 | 2021 | 73 | 0.190 |
Why?
|
Doxycycline | 1 | 2023 | 349 | 0.190 |
Why?
|
Humans | 40 | 2024 | 768166 | 0.180 |
Why?
|
Mitochondria | 1 | 2014 | 3681 | 0.180 |
Why?
|
Cell Line, Tumor | 8 | 2018 | 17140 | 0.180 |
Why?
|
Dermatologic Agents | 1 | 2024 | 313 | 0.170 |
Why?
|
Hidradenitis Suppurativa | 1 | 2023 | 176 | 0.170 |
Why?
|
Tacrolimus | 1 | 2024 | 750 | 0.170 |
Why?
|
Cell Proliferation | 5 | 2018 | 10474 | 0.160 |
Why?
|
Cost Savings | 1 | 2024 | 904 | 0.160 |
Why?
|
Colorectal Neoplasms | 1 | 2018 | 6974 | 0.160 |
Why?
|
Mevalonic Acid | 1 | 2018 | 46 | 0.150 |
Why?
|
Databases, Factual | 2 | 2024 | 8080 | 0.140 |
Why?
|
Seasons | 1 | 2023 | 1524 | 0.140 |
Why?
|
Pteridines | 1 | 2017 | 47 | 0.140 |
Why?
|
Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2017 | 55 | 0.140 |
Why?
|
United States | 6 | 2024 | 73039 | 0.140 |
Why?
|
Gender Identity | 1 | 2023 | 770 | 0.140 |
Why?
|
Mice, Nude | 3 | 2018 | 3623 | 0.140 |
Why?
|
Drug Synergism | 2 | 2018 | 1760 | 0.140 |
Why?
|
5-Methylcytosine | 1 | 2017 | 147 | 0.130 |
Why?
|
Antimalarials | 1 | 2023 | 909 | 0.130 |
Why?
|
Case-Control Studies | 2 | 2024 | 22291 | 0.130 |
Why?
|
Topoisomerase Inhibitors | 1 | 2015 | 19 | 0.130 |
Why?
|
Azocines | 1 | 2015 | 20 | 0.130 |
Why?
|
RNA, Antisense | 1 | 2016 | 136 | 0.130 |
Why?
|
Drug Costs | 1 | 2024 | 1195 | 0.130 |
Why?
|
S-Adenosylmethionine | 1 | 2017 | 219 | 0.130 |
Why?
|
Rheumatic Diseases | 1 | 2022 | 659 | 0.120 |
Why?
|
Hexokinase | 1 | 2015 | 124 | 0.120 |
Why?
|
Fluorodeoxyglucose F18 | 3 | 2015 | 2055 | 0.120 |
Why?
|
Nevus, Pigmented | 1 | 2017 | 222 | 0.120 |
Why?
|
Drug Prescriptions | 1 | 2024 | 1668 | 0.120 |
Why?
|
Anti-Bacterial Agents | 2 | 2023 | 7477 | 0.120 |
Why?
|
Long Interspersed Nucleotide Elements | 1 | 2016 | 332 | 0.110 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2015 | 252 | 0.110 |
Why?
|
Retrospective Studies | 8 | 2023 | 81762 | 0.110 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2018 | 1245 | 0.110 |
Why?
|
Azepines | 1 | 2015 | 329 | 0.110 |
Why?
|
Sexual Behavior | 1 | 2023 | 2197 | 0.110 |
Why?
|
Apoptosis | 4 | 2017 | 9523 | 0.110 |
Why?
|
Nevus | 1 | 2015 | 205 | 0.100 |
Why?
|
Protein Kinase Inhibitors | 3 | 2018 | 5703 | 0.100 |
Why?
|
Cohort Studies | 4 | 2023 | 41754 | 0.100 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2014 | 257 | 0.100 |
Why?
|
Taxoids | 1 | 2015 | 667 | 0.100 |
Why?
|
Antirheumatic Agents | 1 | 2022 | 1381 | 0.100 |
Why?
|
Biological Products | 1 | 2021 | 948 | 0.100 |
Why?
|
Camptothecin | 1 | 2015 | 600 | 0.100 |
Why?
|
Multiprotein Complexes | 2 | 2016 | 1110 | 0.100 |
Why?
|
Immunoblotting | 1 | 2015 | 1647 | 0.100 |
Why?
|
DNA, Neoplasm | 1 | 2017 | 1744 | 0.100 |
Why?
|
Vitamin D Deficiency | 1 | 2021 | 1388 | 0.090 |
Why?
|
Incidence | 3 | 2024 | 21538 | 0.090 |
Why?
|
Adenocarcinoma | 4 | 2015 | 6395 | 0.090 |
Why?
|
Microscopy | 1 | 2016 | 909 | 0.090 |
Why?
|
Protein Processing, Post-Translational | 1 | 2018 | 1966 | 0.090 |
Why?
|
Biological Transport | 1 | 2015 | 2085 | 0.090 |
Why?
|
Pneumonia | 1 | 2022 | 2163 | 0.090 |
Why?
|
Triazoles | 1 | 2015 | 904 | 0.090 |
Why?
|
Neoplasm Invasiveness | 2 | 2016 | 3620 | 0.080 |
Why?
|
Patient Acceptance of Health Care | 1 | 2024 | 3231 | 0.080 |
Why?
|
RNA Interference | 2 | 2016 | 2832 | 0.080 |
Why?
|
Metabolic Networks and Pathways | 1 | 2014 | 801 | 0.080 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2016 | 2062 | 0.080 |
Why?
|
Esophageal Neoplasms | 2 | 2010 | 1668 | 0.080 |
Why?
|
Benzhydryl Compounds | 1 | 2015 | 944 | 0.080 |
Why?
|
Signal Transduction | 5 | 2018 | 23645 | 0.080 |
Why?
|
Immunosuppressive Agents | 1 | 2021 | 4206 | 0.080 |
Why?
|
Female | 11 | 2024 | 397192 | 0.080 |
Why?
|
Healthcare Disparities | 1 | 2024 | 3415 | 0.080 |
Why?
|
DNA Methylation | 3 | 2017 | 4428 | 0.080 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2022 | 5432 | 0.080 |
Why?
|
Paclitaxel | 1 | 2015 | 1733 | 0.070 |
Why?
|
Colon | 1 | 2016 | 1801 | 0.070 |
Why?
|
Male | 10 | 2024 | 364719 | 0.070 |
Why?
|
Analgesics, Opioid | 2 | 2021 | 3837 | 0.070 |
Why?
|
Animals | 10 | 2021 | 169246 | 0.070 |
Why?
|
Positron-Emission Tomography | 3 | 2015 | 6669 | 0.070 |
Why?
|
Mesoderm | 1 | 2010 | 679 | 0.070 |
Why?
|
Indoles | 1 | 2015 | 1836 | 0.070 |
Why?
|
MicroRNAs | 3 | 2017 | 3803 | 0.070 |
Why?
|
Reactive Oxygen Species | 1 | 2014 | 2149 | 0.070 |
Why?
|
Opioid-Related Disorders | 1 | 2021 | 2188 | 0.070 |
Why?
|
Prevalence | 1 | 2023 | 15869 | 0.060 |
Why?
|
Histone Deacetylases | 1 | 2010 | 717 | 0.060 |
Why?
|
Cadherins | 1 | 2010 | 905 | 0.060 |
Why?
|
Sulfonamides | 1 | 2015 | 1982 | 0.060 |
Why?
|
Promoter Regions, Genetic | 1 | 2016 | 5797 | 0.060 |
Why?
|
Adult | 7 | 2024 | 223646 | 0.060 |
Why?
|
Flow Cytometry | 1 | 2015 | 5902 | 0.060 |
Why?
|
Tumor Burden | 3 | 2016 | 1906 | 0.060 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2010 | 4058 | 0.060 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 3251 | 0.050 |
Why?
|
Genome, Human | 1 | 2016 | 4446 | 0.050 |
Why?
|
Energy Metabolism | 1 | 2014 | 2907 | 0.050 |
Why?
|
Cross-Sectional Studies | 1 | 2024 | 26379 | 0.050 |
Why?
|
Carrier Proteins | 1 | 2016 | 4937 | 0.050 |
Why?
|
Neoplasm Metastasis | 1 | 2013 | 4912 | 0.050 |
Why?
|
Skin | 1 | 2016 | 4503 | 0.050 |
Why?
|
Transcription, Genetic | 1 | 2016 | 7608 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2015 | 11878 | 0.050 |
Why?
|
Radiopharmaceuticals | 2 | 2009 | 2735 | 0.050 |
Why?
|
Insurance Carriers | 1 | 2023 | 159 | 0.050 |
Why?
|
Melanocyte-Stimulating Hormones | 1 | 2021 | 25 | 0.050 |
Why?
|
Disease Progression | 2 | 2016 | 13671 | 0.050 |
Why?
|
Risk Factors | 3 | 2024 | 74944 | 0.050 |
Why?
|
Internship and Residency | 1 | 2021 | 5953 | 0.050 |
Why?
|
Receptor, Melanocortin, Type 1 | 1 | 2021 | 74 | 0.050 |
Why?
|
Mice, Inbred C57BL | 2 | 2016 | 22379 | 0.040 |
Why?
|
Young Adult | 2 | 2024 | 60066 | 0.040 |
Why?
|
Receptor, Melanocortin, Type 4 | 1 | 2021 | 131 | 0.040 |
Why?
|
Lasers | 1 | 2023 | 952 | 0.040 |
Why?
|
Hydroxychloroquine | 1 | 2023 | 426 | 0.040 |
Why?
|
Adolescent | 2 | 2024 | 89169 | 0.040 |
Why?
|
Massachusetts | 2 | 2021 | 8890 | 0.040 |
Why?
|
Epithelial Cells | 1 | 2010 | 3703 | 0.040 |
Why?
|
Hair | 1 | 2021 | 508 | 0.040 |
Why?
|
Genome-Wide Association Study | 1 | 2016 | 12795 | 0.030 |
Why?
|
Expressed Sequence Tags | 1 | 2016 | 251 | 0.030 |
Why?
|
Outpatients | 1 | 2024 | 1600 | 0.030 |
Why?
|
Azacitidine | 1 | 2017 | 336 | 0.030 |
Why?
|
Mice, 129 Strain | 1 | 2016 | 369 | 0.030 |
Why?
|
Retroelements | 1 | 2016 | 162 | 0.030 |
Why?
|
Transcription Factors | 1 | 2014 | 12168 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2017 | 8647 | 0.030 |
Why?
|
Health Surveys | 1 | 2024 | 4057 | 0.030 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2012 | 9419 | 0.030 |
Why?
|
Epigenesis, Genetic | 2 | 2017 | 3833 | 0.030 |
Why?
|
Vitamins | 1 | 2021 | 1638 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2016 | 2014 | 0.020 |
Why?
|
Neoplasms | 1 | 2021 | 22371 | 0.020 |
Why?
|
Leadership | 1 | 2021 | 1397 | 0.020 |
Why?
|
Middle Aged | 3 | 2024 | 223492 | 0.020 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2015 | 710 | 0.020 |
Why?
|
Mice | 4 | 2021 | 82029 | 0.020 |
Why?
|
Melanocytes | 1 | 2015 | 509 | 0.020 |
Why?
|
AMP-Activated Protein Kinases | 1 | 2015 | 596 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2023 | 3073 | 0.020 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2015 | 1151 | 0.020 |
Why?
|
Vaccination | 1 | 2022 | 3437 | 0.020 |
Why?
|
Brain | 1 | 2016 | 27360 | 0.020 |
Why?
|
Health Policy | 1 | 2021 | 2698 | 0.020 |
Why?
|
Genome | 1 | 2017 | 1754 | 0.020 |
Why?
|
Down-Regulation | 1 | 2016 | 2937 | 0.020 |
Why?
|
Combined Modality Therapy | 2 | 2012 | 8542 | 0.020 |
Why?
|
Glucose Transporter Type 1 | 1 | 2009 | 186 | 0.020 |
Why?
|
Spheroids, Cellular | 1 | 2010 | 331 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2017 | 1752 | 0.020 |
Why?
|
Vitamin D | 1 | 2021 | 3311 | 0.020 |
Why?
|
Hydroxamic Acids | 1 | 2010 | 483 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2015 | 3611 | 0.020 |
Why?
|
Tissue Array Analysis | 1 | 2009 | 551 | 0.020 |
Why?
|
NF-kappa B | 1 | 2015 | 2493 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2015 | 6231 | 0.020 |
Why?
|
Protease Inhibitors | 1 | 2010 | 751 | 0.020 |
Why?
|
Boronic Acids | 1 | 2010 | 915 | 0.020 |
Why?
|
Neoplasm Staging | 2 | 2012 | 11244 | 0.020 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2012 | 952 | 0.020 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2010 | 778 | 0.020 |
Why?
|
Pneumonectomy | 1 | 2012 | 1156 | 0.020 |
Why?
|
Cell Death | 1 | 2010 | 1679 | 0.010 |
Why?
|
Mental Disorders | 1 | 2024 | 6874 | 0.010 |
Why?
|
Pyrazines | 1 | 2010 | 1205 | 0.010 |
Why?
|
Lymphatic Metastasis | 1 | 2012 | 2914 | 0.010 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2010 | 1319 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2015 | 10760 | 0.010 |
Why?
|
Pandemics | 1 | 2023 | 8748 | 0.010 |
Why?
|
Transforming Growth Factor beta | 1 | 2010 | 1996 | 0.010 |
Why?
|
Transfection | 1 | 2010 | 5755 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2015 | 17622 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2012 | 6847 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2012 | 6526 | 0.010 |
Why?
|
Time Factors | 2 | 2015 | 40218 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2016 | 12543 | 0.010 |
Why?
|
Up-Regulation | 1 | 2010 | 4146 | 0.010 |
Why?
|
Mutation | 2 | 2015 | 30238 | 0.010 |
Why?
|
Neoadjuvant Therapy | 1 | 2012 | 2907 | 0.010 |
Why?
|
Antigens, CD | 1 | 2010 | 4035 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2010 | 4352 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2012 | 12077 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2015 | 9263 | 0.010 |
Why?
|
Cell Movement | 1 | 2010 | 5210 | 0.010 |
Why?
|
Aged | 3 | 2021 | 171504 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2009 | 3603 | 0.010 |
Why?
|
Prognosis | 1 | 2017 | 30010 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2010 | 12800 | 0.010 |
Why?
|
Aged, 80 and over | 2 | 2009 | 59629 | 0.010 |
Why?
|
Prospective Studies | 1 | 2012 | 54926 | 0.000 |
Why?
|